Skip to main content
. 2021 Sep 14;9(9):e002960. doi: 10.1136/jitc-2021-002960

Table 6.

Subgroup and sensitivity analyses

TB events in non-exposure group, (n) TB events in ICI exposure group, (n) HR (95% CI) P value
Subgroup analyses*
 Age 0.98†
  <50 37 1 0.62 (0.09 to 4.55) 0.64
  ≥50 859 19 0.69 (0.44 to 1.09) 0.11
 Sex 0.56†
  Male 676 16 0.71 (0.43 to 1.16) 0.17
  Female 220 4 0.89 (0.33 to 2.42) 0.83
 Cancer subtype 0.98†
  NSCLC 752 19 0.76 (0.48 to 1.19) 0.23
  Urothelial carcinoma 135 0 0.93 (0.06 to 15.15) 0.96
  Melanoma 9 1 0.84 (0.14 to 5.15) 0.85
Sensitivity analyses*
 Defining TB by ICD-10 codes only 1765 44 0.83 (0.61 to 1.12) 0.21
 Excluding TB cases within 30days following cancer diagnosis 637 15 0.89 (0.53 to 1.50) 0.67

*All subgroup and sensitivity analyses were adjusted for age, sex, health insurance type, type of cancer, diabetes, hypertension, chronic lung disease, chronic kidney disease, chronic liver disease, rheumatic disease, active chemotherapy, concomitant immunosuppressant use, concomitant use of corticosteroid, and history of treatment for latent TB infection.

†P value for interaction.

ICD-10, International Classification of Diseases code version 10; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; PS, propensity matching; TB, tuberculosis.